Focal hip cartilage defects and why joint preservation matters

When an MRI or arthroscopy identifies a discrete patch of damaged cartilage in the hip joint, the immediate question for many patients — particularly those in their forties or early fifties — is whether total hip replacement is now inevitable, and if so, how soon.

The clinical picture matters. A focal Grade III or IV cartilage defect is a localised lesion where the surrounding articular surface remains intact and healthy. This is meaningfully different from diffuse Kellgren-Lawrence Grade IV osteoarthritis, where cartilage loss is widespread across the joint and bone-on-bone contact is the defining feature. Femoroacetabular impingement (FAI) is one of the most common upstream causes of focal hip cartilage damage in younger and middle-aged adults, alongside trauma and repetitive loading; because FAI tends to concentrate mechanical stress at a specific point on the femoral head or acetabular rim, it can produce exactly this kind of isolated, bordered defect rather than generalised wear.

Why does deferring replacement matter clinically? Roughly 58% of total hip replacements are estimated to last 25 years. For a 45-year-old, that arithmetic is uncomfortable: a primary replacement performed today could require revision surgery before the age of seventy, and revision carries greater surgical complexity and less predictable outcomes than a primary procedure. Postponing the primary implant by even a decade substantially reduces that risk.

Joint-preservation strategies — including cartilage repair and regenerative injection approaches — aim to relieve pain, restore function, and slow damage progression within the window that exists before focal disease becomes irreversible, diffuse degeneration. This article examines that window specifically in the hip.

What ChondroFiller is and how it works in the hip

ChondroFiller® (branded as Liquid Cartilage™ and manufactured by Meidrix Biomedicals GmbH) is a CE-marked Class III medical device — the same regulatory tier as a hip implant or cardiac pacemaker, reflecting the level of pre-market clinical scrutiny required. The product is an injectable Type I collagen scaffold: a purified structural protein that contains no living cells. 'Acellular' simply means the scaffold arrives blank; the patient's own progenitor cells, drawn in from the surrounding synovium and subchondral bone, populate the matrix and perform the biological work.

The process is called acellular matrix-induced chondrogenesis. Once placed within the focal defect, the collagen material gels in situ — setting to fill the contours of the damaged area — and functions simultaneously as a mechanical cushion and a biological framework. Think of it as an additional layer of padding laid over the worn surface of the hip joint; at the same time, that padding provides the structural environment within which the body's own repair processes can operate. This is not spontaneous cartilage regrowth: ChondroFiller® promotes endogenous repair by giving host cells the conditions they need, rather than delivering those cells itself.

At the Lincolnshire Hip clinic in Grantham and Sleaford — a hip-specialist service led by Professor Paul Lee — the current pathway delivers ChondroFiller® as an outpatient, ultrasound-guided injection. No theatre admission, no general anaesthetic, and no surgical incision are involved.

What the clinical evidence actually shows

The strongest hip-specific outcome on record is a Harris Hip Score improvement of +33 points, reported in published peer-reviewed clinical studies and collated in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025). The Harris Hip Score is a validated 100-point index covering pain, function, and range of motion; an improvement of this magnitude substantially exceeds the threshold considered clinically meaningful.

MRI evidence indicates that tissue-level change is occurring. MOCART scores — a standardised imaging scale used to grade cartilage repair quality — range from 70 to 87 across joint applications, with published series recording scores above 81 at one year, indicating that more than 80% of the target defect is filled and the repair tissue integrates with the surrounding native cartilage. Scores progress from roughly 65 at four weeks to 81 at twelve months, reflecting gradual scaffold maturation rather than an immediate result.

On safety and durability, the reoperation rate sits between 3% and 8% — a direct outcome measure, not a projection. Comparable figures for microfracture reach up to 41% and for autologous chondrocyte implantation (ACI/MACI) up to 37%; the complication rate across more than 19,000 ChondroFiller® procedures globally is reported at approximately 0%.

One limitation deserves a plain statement. The hip-specific data derives principally from the manufacturer's CER rather than from independent randomised trials; the knee evidence base is considerably more mature. No study has enrolled hip patients and tracked time-to-replacement as a primary endpoint. The +33-point Harris Hip Score gain is a clinically real signal, but it quantifies pain and function improvement — not how many years of replacement surgery it may defer. That question remains, for now, unanswered in the published literature.

How ChondroFiller compares with other cartilage repair approaches

Putting ChondroFiller® in context requires a brief look at the two most established surgical alternatives for focal cartilage defects: microfracture and autologous chondrocyte implantation (ACI/MACI).

Microfracture is a marrow-stimulation technique delivered arthroscopically, in which small perforations are made through the subchondral bone to draw marrow cells into the defect. The repair tissue that forms is fibrocartilage — mechanically inferior to native hyaline cartilage — which may partly explain why published series report reoperation rates reaching up to 41%. It remains a widely used procedure, but durability is a genuine consideration.

ACI and MACI involve two stages: an initial cell-harvesting operation followed by a separate surgical implantation. That added procedural burden — two theatre episodes, two recovery periods — is considerable, and reoperation rates of up to 37% have been reported in the literature. The trade-off is a cell-based approach in exchange for greater complexity from the outset.

ChondroFiller®, by contrast, is placed as an outpatient collagen scaffold injection under ultrasound guidance: no theatre, no general anaesthetic, no incision. For working-age patients balancing employment and family commitments, that practical difference in recovery burden is meaningful rather than incidental.

One point of alignment across all three approaches: they are each designed for isolated, focal cartilage defects with healthy surrounding tissue. None is an appropriate substitute for total hip replacement when diffuse, end-stage disease has established throughout the hip joint.

The 'delay replacement' question — what the evidence can and cannot claim

The clinical logic behind joint preservation sits on firmer ground than an absence of trial data might suggest. Hip osteoarthritis typically advances slowly — symptoms of pain, stiffness, and reduced range of motion accumulating over years rather than months — which means that for patients with focal, contained cartilage damage, a genuine intervention window exists before diffuse degeneration spreads across the whole joint surface.

Within that window, the role of a collagen scaffold treatment is to support the body's own repair processes, reduce mechanical friction on the surrounding articular surface, and restore enough function to maintain an active daily life without replacement. Whether this translates to one additional year before surgery or several is a question the current evidence cannot resolve in precise numerical terms — that limitation has already been set out plainly. What the evidence can say is that a joint performing well at twelve months is a joint that has not yet required replacement, and that sustained, validated functional gains carry real-world value independent of any countdown.

The preservation-window argument is strongest for a specific patient profile: younger or middle-aged adults with focal Grade III or IV cartilage damage arising from femoroacetabular impingement or trauma, healthy cartilage at the defect margins, and no sign of diffuse joint-wide degeneration. For that group, the slow natural history of hip osteoarthritis and the capacity of a contained defect to respond to scaffold repair together make a preservation strategy clinically coherent — not a guarantee, but a reasoned option that a structured clinical assessment is designed to evaluate.

Who is suitable and how Lincolnshire Hip assesses candidates

Patients most likely to benefit from an injectable collagen scaffold have an isolated, focal area of Grade III or IV cartilage damage — a contained lesion, not joint-wide wear — with healthy surrounding cartilage capable of anchoring the repair. Femoroacetabular impingement is one of the more common upstream causes of exactly this pattern, particularly in younger and middle-aged adults; those who carry an FAI diagnosis, or who have had FAI-related surgery in the past, should raise cartilage assessment as part of any hip evaluation rather than assuming the matter is settled.

Two assumptions regularly put patients off seeking assessment unnecessarily. There is no strict upper age limit for ChondroFiller®. And a finding of 'bone on bone' on plain X-ray does not automatically close the door: the injection pathway may still offer a mechanical cushioning role where some articular surface remains, even in more advanced — though not end-stage — disease. Assessment, not assumption, determines what is possible.

At Lincolnshire Hip, suitability is evaluated across four clinical dimensions. The mechanical environment of the joint — load distribution, defect geometry, and residual joint space — is considered first, because no regenerative scaffold can succeed in a mechanically hostile setting. The biological quality of the surrounding cartilage and synovial tissue determines whether the scaffold has viable host cells to recruit. The patient's own healing biology — including systemic health, activity baseline, and bone quality — shapes the repair capacity that the collagen matrix has to work with. Timing, finally, reflects where the patient sits on the disease trajectory: early focal damage, established but contained lesions, and more diffuse wear each call for a different intervention, or a staged combination.

That clinical picture, read across all four dimensions, is what determines the most appropriate pathway — not any single scan finding or age bracket. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without a GP referral, with assessment available locally in Grantham and Sleaford.

1. [1] Femoroacetabular impingement. https://en.wikipedia.org/?curid=20754811 https://en.wikipedia.org/?curid=20754811
2. [2] Osteoarthritis. https://en.wikipedia.org/?curid=504841 https://en.wikipedia.org/?curid=504841
3. [3] Articular cartilage repair. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351